Fondaparinux versus Enoxaparin in Acute Coronary Syndromes

To the Editor: The authors of the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS-5) study (April 6 issue)¹ point out that despite the presence or absence of administration of unfractionated heparin, bleeding rates were significantly lower with fondaparinux than with enoxaparin in patients with acute coronary syndromes. However, the authors do not fully evaluate the significant difference between patients who received unfractionated heparin after randomization in the enoxaparin group and those who did so in the fondaparinux group (31.2 percent and 22.0 percent, respectively; P<0.001) (Table 1 in the article).Of the patients who underwent percutaneous coronary . . .